Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

J Clin Oncol. 2015 Aug 1;33(22):2484-5. doi: 10.1200/JCO.2014.60.6954. Epub 2015 Jun 1.

¹ Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris VII Diderot, Clichy, France mohamed.bouattour@bjn.aphp.fr.
² Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil Université, INSERM U 955 Team 18, Paris, France.
³ Pitié-Salpêtrière University Hospital, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie Paris VI, Paris, France.
⁴ Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris VII Diderot, Clichy, France.
⁵ Angiogenesis Inhibitors Multidisciplinary Study Group, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.

No abstract available

Publication types